Electronic Storage No.:
2 3 3
Worldwide Scientific Affairs

REQUEST FOR APPLICATIONS AVAILABLE

Philip Morris Incorporated announces the availability of its 2000 Request for Applications booklet for the Philip Morris External Research Program. The broad range of research interests includes the following scientific areas: Exposure/Biomarkers/Dosimetry, Epidemiological Research, Clinical and Model Systems Research, and Tobacco Smoke and Smoking Behavior. Applications must be received by November 1, 2000.

For more information or a copy of the Request for Applications booklet, please call or write:

Research Management Group
Attn: Research Manager
1099 Winterson Road, Suite 280
Linthicum Heights, Maryland USA 21090
Telephone: (410) 684-3782
Fax: (410) 684-3729
Email: rmgroup2000@aol.com



National NeuroAIDS Tissue Consortium

The National NeuroAIDS Tissue Consortium (NNTC) is now soliciting requests from qualified investigators for tissue specimens for research projects in NeuroAIDS. Requests can be made for the central and peripheral nervous tissues, cerebrospinal fluid and blood collected from HIV infected donors. Tissue samples are banked from donors for whom comprehensive neuromedical and neuropsychiatric data were gathered antemortem.

The NNTC is a national research resource and is supported by the National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Drug Abuse (NIDA). The Consortium now includes four specialized brain banks in Los Angeles (VAMC-West Los Angeles, Elyse Singer, MD, Director), New York (Mount Sinai Medical Center, Susan Morgello, MD, Director), Galveston (University of Texas, Medical Branch, Benjamin Gelman, MD, Ph.D., Director) and San Diego (University of California-San Diego, Igor Grant, MD, Director).

Inquiries can be directed to the National Coordinating Office (NCO) for the NNTC (Piotr B. Kozlowski, MD, Ph.D., Director, NNTC NCO, 1050 Forest Hill Road, Staten Island, NY 10314, E-mail: pbk@hivbrainbanks.org or pbk@nntc.org; Phone: 1-800-510-1678 or 718-494-5161, FAX: 718-494-5347).
Website: http://www.hivbrainbanks.org.

THE NATIONAL ACADEMIES
Advisers to the Nation on Science, Engineering, and Medicine
National Academy of Sciences
National Academy of Engineering
Institute of Medicine
National Research Council

Christine Mirzayan Internship Program

The **Christine Mirzayan Internship Program of the National Academies** is designed to engage graduate and postdoctoral science, engineering, medical, veterinary, business, and law students in science and technology policy and to familiarize them with the interactions between science, technology, and government. As a result, students develop essential skills different from those attained in academia and make the transition from being a graduate student to a professional.

For the year 2001, the internship program will comprise two sessions: January 16 through April 6 (12 weeks) and June 4 through August 10 (10 weeks).

To apply, candidates should submit the application and one letter of reference, both available on-line at *national-academies.org/internship*.

The deadline for receipt of materials is November 1 for the January 2001 program and March 1 for the June 2001 program.

Details are on our website:
national-academies.org/internship

Additional questions should be directed to:
internship@nas.edu

INTERN WITH EINSTEIN

NOTICE: RAPID ACCESS TO PREVENTIVE INTERVENTION DEVELOPMENT — "RAPID"

National Cancer Institute

The National Cancer Institute announces the ongoing initiative: Rapid Access to Preventive Intervention Development (RAPID). RAPID will make available to academic investigators the preclinical and early clinical drug development contract resources of NCI's Division of Cancer Prevention. The goal of RAPID is the rapid movement of novel molecules and concepts from the laboratory to the clinic for clinical trials of efficacy. RAPID will assist investigators who submit successful requests by providing any (or all) of the pre-clinical and phase 1 clinical developmental requirements for phase 2 clinical efficacy trials. These include, for example, preclinical pharmacology, toxicology, and efficacy studies; bulk supply, GMP manufacturing, and formulation; and regulatory and IND support and phase 1 clinical studies. Suitable types of agents for RAPID may range from single chemical or biological entities to defined complex mixtures with the potential to prevent, reverse, or delay carcinogenesis. For more detailed information, visit the web site: **http://dcp.nci.nih.gov/CB/**

Requests for RAPID resources are to be submitted as described in the web site. Written requests will be evaluated by a specially constituted RAPID panel, consisting of selected NCI staff and outside experts from academia and industry. Requests must be received on or before November 21, 2000. Applications should be submitted directly to the office listed below. Inquiries are encouraged, and the opportunity to clarify issues or questions is welcome. This notice has also been published in the NIH Guide. Please contact:

RAPID
James A. Crowell, Ph.D.
Division of Cancer Prevention, NCI
Executive Plaza North, Suite 201
6130 Executive Blvd.
Bethesda, MD 20892
Rockville, MD 20852 (for express/courier service)
telephone (301) 594-0459
fax (301) 402-0553, (301) 594-2943
email: jc94h@nih.gov

PM3001180699

Source: https://www.industrydocuments.ucsf.edu/docs/pyfk0001